dc.contributor.author
Koppold, Daniela A.
dc.contributor.author
Kandil, Farid I.
dc.contributor.author
Müller, Anna
dc.contributor.author
Güttler, Oliver
dc.contributor.author
Steckhan, Nico
dc.contributor.author
Meiss, Sara
dc.contributor.author
Breinlinger, Carolin
dc.contributor.author
Nelle, Esther
dc.contributor.author
Rajput Khokhar, Anika
dc.contributor.author
Jeitler, Michael
dc.contributor.author
Hanslian, Etienne
dc.contributor.author
Fischer, Jan Moritz
dc.contributor.author
Michalsen, Andreas
dc.contributor.author
Kessler, Christian S.
dc.date.accessioned
2025-07-29T07:45:45Z
dc.date.available
2025-07-29T07:45:45Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/48460
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-48182
dc.description.abstract
Fibromyalgia syndrome (FMS) is a common chronic pain disorder and often occurs as a concomitant disease in rheumatological diseases. Managing FMS takes a complex approach and often involves various non-pharmacological therapies. Fasting interventions have not been in the focus of research until recently, but preliminary data have shown effects on short- and medium-term pain as well as on physical and psychosomatic outcomes in different chronic pain disorders. This single-arm observational study investigated the effects of prolonged fasting (3-12 days, <600 kcal/d) embedded in a multimodal treatment setting on inpatients with FMS. Patients who were treated at the Department of Internal Medicine and Nature-Based Therapies of the Immanuel Hospital Berlin, Germany, between 02/2018 and 12/2020 answered questionnaires at hospital admission (V0) and discharge (V1), and then again three (V2), six (V3), and 12 (V4) months later. Selected routine blood and anthropometric parameters were also assessed during the inpatient stay. A total of 176 patients with FMS were included in the study. The Fibromyalgia Impact Questionnaire (FIQ) total score dropped by 13.7 +/- 13.9 (p < 0.001) by V1, suggesting an improvement in subjective disease impact. Pain (NRS: reduction by 1.1 +/- 2.5 in V1, p < 0.001) and quality of life (WHO-5: +4.9 +/- 12.3 in V1, p < 0.001) improved, with a sustainable effect across follow-up visits. In contrast, mindfulness (MAAS: +0.3 +/- 0.7 in V1, p < 0.001), anxiety (HADS-A: reduction by 2.9 +/- 3.5 in V1, p < 0.0001), and depression (HADS-D: reduction by 2.7 +/- 3.0 in V1, p < 0.0001) improved during inpatient treatment, without longer-lasting effects thereafter. During the study period, no serious adverse events were reported. The results suggest that patients with FMS can profit from a prolonged therapeutic fasting intervention integrated into a complex multimodal inpatient treatment in terms of quality of life, pain, and disease-specific functional parameters.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
fibromyalgia
en
dc.subject
musculoskeletal pain
en
dc.subject
caloric restriction
en
dc.subject
integrative medicine
en
dc.subject
complementary medicine
en
dc.subject
prolonged fasting
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Effects of Prolonged Medical Fasting during an Inpatient, Multimodal, Nature-Based Treatment on Pain, Physical Function, and Psychometric Parameters in Patients with Fibromyalgia: An Observational Study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
1059
dcterms.bibliographicCitation.doi
10.3390/nu16071059
dcterms.bibliographicCitation.journaltitle
Nutrients
dcterms.bibliographicCitation.number
7
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
16
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
38613092
dcterms.isPartOf.eissn
2072-6643